Skip To Main Content
Rupert Bartsch on Muck Rack

Rupert Bartsch

As seen in: Nature, Frontiers in Medicine, MDPI, Medscape, The Lancet, ONCOLOGY journal, OncLive, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rupert

Contact Rupert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort

|
By Kerstin Wimmer, Ruth Exner, Rupert Bartsch, Zsuzsanna Bago-Horvath, Stefan Konrad, Florian Fitzal, Maximilian Marhold, Katharina Kantner
| Frontiers in Medicine
Abstract Background: Neoadjuvant systemic therapy (NST) has become a cornerstone in the management of aggressive early breast cancer (BC) subtypes, including triple-negative (eTNBC) and HER2-positive disease. Immune checkpoint inhibition with pembrolizumab represents an active immunotherapeutic approach, whereas dual HER2 blockade with trastuzumab and pertuzumab constitutes passive immunotherapy in early HER2-positive BC.
Open in Who Shared Issue with article?

109 Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR

|
By Diana Lüftner, Rupert Bartsch, Urs Breitenstein
| ONCOLOGY journal Verified
Background Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor approved in Europe as extended adjuvant treatment for adult patients with HER2-positive/hormone receptor–positive early breast cancer who completed adjuvant trastuzumab-based therapy less than 1 year ago. In the phase 3 ExteNET study, neratinib significantly improved 2-year invasive disease-free survival (iDFS) (Δ4.5%, HR,0.49; 95% CI, 0.30-0.78) with an iDFS rate of 95.3% for neratinib.
Open in Who Shared Issue with article?

Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials

|
By Rupert Bartsch, Christian F. Singer, Maximilian Marhold, Maximilian Hochmair, Kathrin Strasser-Weippl, Simon Udovica, Clemens Leitgeb, Christian Peters-Engl, Verena Sagaster, Muna Ferner, Wolfgang Hilbe
| Nature Verified
Abstract Interstitial lung disease (ILD) is a common and potentially life-threatening adverse event associated with trastuzumab deruxtecan (T-DXd). In the pivotal T-DXd clinical trials, 10–15% of patients developed ILD, with stringent mitigation strategies aimed at the early detection of low-grade cases. Real-world data are urgently needed to assess ILD incidence and outcomes outside controlled trial settings.
Open in Who Shared Issue with article?
See all 11 licensed articles (13 Total)